Literature DB >> 28581332

PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.

Lu Han1,2, Wen-Jun Shen1,2, Stefanie Bittner1, Fredric B Kraemer1,2, Salman Azhar1,2.   

Abstract

This article provides a comprehensive review about the molecular and metabolic actions of PPAR-α. It describes its structural features, ligand specificity, gene transcription mechanisms, functional characteristics and target genes. In addition, recent progress with the use of loss of function and gain of function mouse models in the discovery of diverse biological functions of PPAR-α, particularly in the vascular system and the status of the development of new single, dual, pan and partial PPAR agonists (PPAR modulators) in the clinical management of metabolic diseases are presented. This review also summarizes the clinical outcomes from a large number of clinical trials aimed at evaluating the atheroprotective actions of current clinically used PPAR-α agonists, fibrates and statin-fibrate combination therapy.

Entities:  

Keywords:  NAFLD; cardiovascular disease; dyslipidemia; fibrates; insulin resistance; lipid and glucose homeostasis; metabolic diseases; obesity

Mesh:

Substances:

Year:  2017        PMID: 28581332      PMCID: PMC5941715          DOI: 10.2217/fca-2016-0059

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  154 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 3.  International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Authors:  Liliane Michalik; Johan Auwerx; Joel P Berger; V Krishna Chatterjee; Christopher K Glass; Frank J Gonzalez; Paul A Grimaldi; Takashi Kadowaki; Mitchell A Lazar; Stephen O'Rahilly; Colin N A Palmer; Jorge Plutzky; Janardan K Reddy; Bruce M Spiegelman; Bart Staels; Walter Wahli
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

4.  The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.

Authors:  Christophe Blanquart; Roxane Mansouri; Réjane Paumelle; Jean-Charles Fruchart; Bart Staels; Corine Glineur
Journal:  Mol Endocrinol       Date:  2004-05-06

5.  Identification of a physiologically relevant endogenous ligand for PPARalpha in liver.

Authors:  Manu V Chakravarthy; Irfan J Lodhi; Li Yin; Raghu R V Malapaka; H Eric Xu; John Turk; Clay F Semenkovich
Journal:  Cell       Date:  2009-07-30       Impact factor: 41.582

Review 6.  PPARalpha in atherosclerosis and inflammation.

Authors:  Fokko Zandbergen; Jorge Plutzky
Journal:  Biochim Biophys Acta       Date:  2007-05-21

7.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

8.  A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).

Authors:  Rajendrakumar H Jani; Vikas Pai; Pramod Jha; Gunjan Jariwala; Satinath Mukhopadhyay; Anil Bhansali; Shashank Joshi
Journal:  Diabetes Technol Ther       Date:  2013-10-18       Impact factor: 6.118

9.  Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Authors:  Bertrand Cariou; Rémy Hanf; Stéphanie Lambert-Porcheron; Yassine Zaïr; Valérie Sauvinet; Benoit Noël; Laurent Flet; Hubert Vidal; Bart Staels; Martine Laville
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

10.  Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.

Authors:  Sin Gon Kim; Doo Man Kim; Jeong-Taek Woo; Hak Chul Jang; Choon Hee Chung; Kyung Soo Ko; Jeong Hyun Park; Yong Soo Park; Sang Jin Kim; Dong Seop Choi
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more
  44 in total

1.  Proanthocyanidins of Natural Origin: Molecular Mechanisms and Implications for Lipid Disorder and Aging-Associated Diseases.

Authors:  Yu Nie; Stephen R Stürzenbaum
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

2.  Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH).

Authors:  Lu Han; Stefanie Bittner; Dachuan Dong; Yuan Cortez; Hunter Dulay; Sara Arshad; Wen-Jun Shen; Fredric B Kraemer; Salman Azhar
Journal:  Mol Cell Endocrinol       Date:  2019-08-12       Impact factor: 4.102

Review 3.  PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.

Authors:  Lu Han; Wen-Jun Shen; Stefanie Bittner; Fredric B Kraemer; Salman Azhar
Journal:  Future Cardiol       Date:  2017-06-05

4.  Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.

Authors:  Letizia Giampietro; Antonio Laghezza; Carmen Cerchia; Rosalba Florio; Lucia Recinella; Fabio Capone; Alessandra Ammazzalorso; Isabella Bruno; Barbara De Filippis; Marialuigia Fantacuzzi; Claudio Ferrante; Cristina Maccallini; Paolo Tortorella; Fabio Verginelli; Luigi Brunetti; Alessandro Cama; Rosa Amoroso; Fulvio Loiodice; Antonio Lavecchia
Journal:  ACS Med Chem Lett       Date:  2019-02-25       Impact factor: 4.345

5.  PPAR-α knockout leads to elevated blood pressure response to angiotensin II infusion associated with an increase in renal α-1 Na+/K+ ATPase protein expression and activity.

Authors:  Syed J Khundmiri; Carolyn M Ecelbarger; Joycemary Amponsem; Hong Ji; Kathryn Sandberg; Dexter L Lee
Journal:  Life Sci       Date:  2022-03-01       Impact factor: 5.037

6.  Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1.

Authors:  Rachel J Perry
Journal:  Diabetes       Date:  2022-09-01       Impact factor: 9.337

Review 7.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

8.  Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver.

Authors:  Xiaoyue Pan; Gary J Schwartz; M Mahmood Hussain
Journal:  J Lipid Res       Date:  2018-10-28       Impact factor: 5.922

Review 9.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

10.  Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Yan Fan; Long-Teng Yan; Zheng Yao; Guang-Yi Xiong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-09       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.